Dexcom, Inc., San Diego, California, USA.
Optum Life Sciences, Inc., Eden Prairie, Minnesota, USA.
Diabetes Technol Ther. 2022 Jul;24(7):520-524. doi: 10.1089/dia.2021.0525. Epub 2022 Apr 27.
Little is known about the impact of real-time continuous glucose monitoring (rtCGM) on diabetes-related medical costs within the type 2 diabetes (T2D) population. A retrospective analysis of administrative claims data from the Optum Research Database was conducted. Changes in diabetes-related health care resource utilization costs were expressed as per-patient-per-month (PPPM) costs. A total of 571 T2D patients (90% insulin treated) met study inclusion criteria. Average PPPM for diabetes-related medical costs decreased by -$424 (95% confidence interval [CI] -$816 to -$31, = 0.035) after initiating rtCGM. These reductions were driven, in part, by reductions in diabetes-related inpatient medical costs: -$358 (95% CI -$706 to -$10, = 0.044). Inpatient hospital admissions were reduced on average -0.006 PPPM ( = 0.057) and total hospital days were reduced an average of -0.042 PPPM ( = 0.139). These findings provide real-world evidence that rtCGM use was associated with diabetes-related health care resource utilization cost reductions in patients with T2D.
实时连续血糖监测 (rtCGM) 对 2 型糖尿病 (T2D) 人群中糖尿病相关医疗费用的影响知之甚少。对 Optum Research Database 中的行政索赔数据进行了回顾性分析。糖尿病相关医疗资源利用成本的变化以每位患者每月 (PPPM) 成本表示。共有 571 名 T2D 患者 (90%接受胰岛素治疗) 符合研究纳入标准。启动 rtCGM 后，糖尿病相关医疗费用的平均 PPPM 降低了 -$424(95%置信区间 [-$816，-$31]， = 0.035)。这些减少部分归因于糖尿病相关住院医疗费用的减少：-$358(95%置信区间 [-$706，-$10]， = 0.044)。平均而言，住院医院就诊次数减少了 -0.006 PPPM( = 0.057)，总住院天数减少了 -0.042 PPPM( = 0.139)。这些发现提供了真实世界的证据，表明 rtCGM 的使用与 T2D 患者的糖尿病相关医疗资源利用成本降低有关。
